



Last Updated: September 4, 2008

## Corrections to the Low Cost Alternative/Reference Drug Program (LCA/RDP) Booklet

We regret any inconvenience caused by errors in the LCA/RDP Booklet that came into effect on July 28, 2008. Following is a detailed list of corrections. Additional corrections may be added to this list in the coming days.

Wherever possible, we will amend the online booklet to reflect these corrections.

The most recent corrections are indicated in **red**. Corrections incorporated into the booklet will be identified in this list with the symbol  .

The following corrections are effective immediately. Please note that LCA prices for some of the categories have been revised, including the Pramipexole Tab 1.5mg LCA category.

DIN	DRUG NAME	NEW LCA STATUS	NEW LCA PRICE
<b>MIRTAZAPINE TAB 15mg</b>			
2279894	Novo Mirtazapine OD Tab 15mg	F	
2250594	Sandoz-Mirtazapine Tab 15 mg	F	
2248542	Remeron RD Tab 15mg	P	\$0.3808
2256096	Gen-Mirtazapine Tab 15mg	P	\$0.3808
2273942	PMS-Mirtazapine Tab 15mg	P	\$0.3808
2286610	Apo-Mirtazapine Tab 15mg	P	\$0.3808
<b>SALBUTAMOL TAB 4mg</b>			
2165376	Nu-Salbutamol Tab 4mg	F	
2146851	Apo-Salvent Tab 4mg	F	
<b>CLOXACILLIN 250 mg Cap</b>			
337765	Novo-Cloxin Cap 250mg	F	
717584	Nu-Cloxi Cap 250mg	F	
618292	Apo Cloxi Cap 250mg	F	
<b>CLOXACILLIN 500 mg Cap</b>			
337773	Novo-Cloxin Cap 500mg	F	
717592	Nu-Cloxi Cap 500mg	F	
618284	Apo Cloxi Cap 500mg	F	

DIN	DRUG NAME	NEW LCA STATUS	NEW LCA PRICE
<b>CLOXACILLIN PWR/SOL 25mg/mL</b>			
337757	Novo-Cloxin for Oral Soln 125mg/5mL	F	
717630	Nu-Cloxi Sol 125mg/5mL	F	
644633	Apo-Cloxi for Oral Soln 125mg/5mL	F	
<b>AMOXICILLIN SUS/PWR 25mg</b>			
865540	Nu-Amoxi Sus 125/5mL	F	
1934171	Novamoxin Sus 25mg/mL sugar-reduced	F	
452149	Novamoxin Sus 125mg/5mL	P	\$0.0367
628131	Apo-Amoxi PWR for Susp 125mg/5mL	F	
2230245	PMS-Amoxicillin Sus 125mg/5mL	F	
<b>AMOXICILLIN SUS/PWR 50mg</b>			
865559	Nu-Amoxi Sus 250mg/5mL	F	
1934163	NovAmoxin 250 Sus 50mg/mL sugar-reduced	F	
2230246	PMS-Amoxicillin Sus 250mg/5mL	F	
452130	NovAmoxin Sus 250mg/5mL	F	
628158	Apo-Amoxi PWR for Susp 250mg/5mL	P	\$0.0561
<b>PRAMIPEXOLE TAB 1.5mg</b>			
2269333	Novo-Pramipexole Tab 1.5mg	F	
2237147	Mirapex Tab 1.5mg	P	\$1.4200
2292408	Apo-Pramipexole Tab 1.5mg	P	\$1.4200
2290154	PMS-Pramipexole Tab 1.5mg	F	

F – Fully covered      P – Partially covered

**Risperidone 4mg tablets LCA Price change**—Effective August 23, 2008, the LCA price for the Risperidone 4mg LCA category will be changed to 2.5289.

DIN	DRUG NAME	New LCA Status	New LCA Price
<b>RISPERIDONE TAB 4MG</b>			
2252066	Pms-Risperidone	F	
2282291	Gen-Risperidone	F	
2025310	Risperdal	P	2.5289
2264811	Ratio Risperidone	P	2.5289
2279835	Sandoz Risperidone	P	2.5289
2280957	Ran-Risperidone	P	2.5289
2282178	Apo-Risperidone	P	2.5289
2264234	Novo-Risperidone	F	
2282631	Co-Risperidone	F	

F – Fully covered      P – Partially covered

**Famciclovir 125mg, 250mg and 500mg Tabs**—Effective immediately the following Low Cost Alternative categories have been corrected.

DIN	DRUG NAME	LCA Status	LCA Price
<b>FAMCICLOVIR TAB 125MG</b>			
2278634	Sandoz Famciclovir tab 125mg	F	
2229110	Famvir tab 125mg	P	\$2.0240
2292025	Apo-Famciclovir tab 125mg	P	\$2.0240
<b>FAMCICLOVIR TAB 250MG</b>			
2278642	Sandoz Famciclovir tab 250mg	F	
2229129	Famvir tab 250mg	P	\$2.7200
2292041	Apo-Famciclovir tab 250mg	P	\$2.7200
<b>FAMCICLOVIR TAB 500MG</b>			
2278650	Sandoz Famciclovir tab 500mg	F	
2177102	Famvir tab 500mg	P	\$4.3559
2292068	Apo-Famciclovir tab 500mg	P	\$4.3559

F – Fully covered      P – Partially covered

**Ranitidine follow-up:** Effective August 19, 2008, the PSD Low Cost Alternative categories for ranitidine will return to the LCA designations indicated in the July 28, 2008, LCA/RDP Booklet:

- For ranitidine 150mg and 300mg tabs: Zantac is a full benefit if RDP special authority is in place (i.e., designated as P\*). All other generic ranitidine tablets are partial LCA benefits.

**Effective immediately**, the following LCA categories have been revised.

DIN	DRUG NAME	New LCA Status	LCA Price
<b>PREDNISOLONE ACETATE DROPS 1%</b>			
700401	Ratio-Prednisolone Dps 1%	F	
2023768	Diopred Susp 1%	P	1.5294
1916203	Sandoz Prednisolone Dps 1%	F	
301175	Pred Forte Dps 1%	P	1.5294
<b>PRAMIPEXOLE TAB Tab 0.5mg</b>			
2292386	Apo-Pramipexole Tab 0.5mg	F	
2269317	Novo-Pramipexole Tab 0.5mg	P	1.1670
2241594	Mirapex Tab 0.5mg	P	1.1670
2290138	PMS-Pramipexole Tab 0.5mg	F	
<b>PRAMIPEXOLE TAB 1.5mg</b>			
2269333	Novo-Pramipexole Tab 1.5mg	F	
2237147	Mirapex Tab 1.5mg	P	1.0580
2292408	Apo-Pramipexole Tab 1.5mg	P	1.0580
2290154	PMS-Pramipexole Tab 1.5mg	F	

F – Fully covered      P – Partially covered

**Apo-Ticlopidine 250 mg tablets & Novo-Difenac 75 & 100mg tablets:** Information on these products was omitted from the LCA/RDP Booklet that came into effect on July 28, 2008.

DIN	DRUG NAME	LCA Status	LCA Price
2237701	APO-TICLOPIDINE 250 mg tablet	P	0.7105
2158582	NOVO-DIFENAC SR 75 mg tablet	P*	
2048698	NOVO-DIFENAC SR 100 mg tablet	P*	

P – Partially covered    P\* – Drug is a partial benefit if Special Authority is in place when the prescription is filled.

**Risperidone 4mg tablets:** The risperidone 4mg tablet LCA category was revised effective **August 9, 2008**.

DIN	DRUG NAME	LCA Status	LCA Price
2252066	PMS-RISPERIDONE	F	
2282291	GEN-RISPERIDONE	F	
2264234	NOVO RISPERIDONE	F	
2282631	CO RISPERIDONE	F	
2025310	RISPERDAL	P	1.6743
2264811	RATIO RISPERIDONE	P	1.6743
2279835	SANDOZ RISPERIDONE	P	1.6743
2280957	RAN-RISPERIDONE	P	1.6743
2282178	APO RISPERIDONE	P	1.6743

F – Fully covered    P – Partially covered

### Ranitidine:

All ranitidine DINs are eligible for full PharmaCare coverage from **August 1 to August 18, 2008**. This interim coverage will assist pharmacies experiencing supply delays and allow them to adjust stock without disruption to patient care.

Please note that the current LCA/RDP Booklet provided the usual 45 days notification of changes to LCA categories and the manufacturer confirmed that the full benefit ranitidine product is available for distribution. However, some pharmacies have reported that distributors are unable to provide adequate supplies at this time.

**Levothyroxine:** We regret any inconvenience caused by the inadvertent inclusion of levothyroxine products in the LCA Program. Their inclusion was a result of a data error in PharmaNet. As of July 30, 2008, all levothyroxine products were removed from the LCA Program. All strengths of levothyroxine are regular benefits, eligible for full coverage subject to the usual rules of a patient's PharmaCare plan, including any annual deductible requirement. Please note that although PharmaNet required correction, the products were not included in the LCA/RDP Booklet that came into effect on July 28, 2008.